Modular Medical Secures Coverage Agreements with All Three of the Nation's Largest PBMs for Pivot Insulin Delivery System
Key Highlights
- ➤Modular Medical (MODD) secures agreements with all three largest U.S. PBMs
- ➤PBM networks collectively cover more than 182 million lives
- ➤Top three PBMs process approximately 80% of U.S. prescription claims
- ➤Pivot coverage remains subject to individual formulary and benefit decisions
- ➤Agreements support Modular Medical’s planned commercial rollout over the coming year
Expert Statements
Jeb Besser, Chief Executive Officer of Modular Medical
“Securing agreements with all three of the nation's largest PBMs marks a significant milestone in expanding access to Pivot”
Jeb Besser, Chief Executive Officer of Modular Medical
“These contracts establish an important foundation for broader patient access through standard pharmacy benefits and support our commercial rollout over the coming year.”
Mark Brady, Director of Managed Markets at Modular Medical
“Access remains one of the most important factors influencing the adoption of insulin pump therapy”
Mark Brady, Director of Managed Markets at Modular Medical
“Securing these agreements supports our core strategy of making Pivot both accessible and affordable, and we believe it will help reduce traditional coverage barriers so more patients can transition from multiple daily injections to advanced pump therapy.”
SAN DIEGO, CA / ACCESS Newswire / November 19, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot(™) tubeless patch pump, today announced that it has entered into agreements with the remaining two of the nation's three largest pharmacy benefit managers ("PBMs") for its Pivot tubeless patch pump. With these agreements, Modular Medical has now entered into agreements with all three of the nation's largest PBMs, whose networks collectively cover more than 182 million lives and process approximately 80% of U.S. prescription claims.(1) Coverage for any individual patient remains subject to the formulary decisions and benefit design of the applicable health plan or plan sponsor.
Drug Channels Institute estimates the top three PBMs consistently process 80% of all equivalent prescription claims(2), making comprehensive PBM coverage a critical catalyst for broad commercial distribution.
Get started
Create a free account to read the full story.
